HIGHLIGHTS
- who: Carmen Mestre-Duru00e1n and colleagues from the Sapienza University of Rome, Italy have published the article: Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells, in the Journal: (JOURNAL)
- what: This study showed the effects of ruxolitinib on TLR4 and TLR9 ligandactivated NK cells from healthy donors. All patients or legal guardians signed an institutionally approved informed consent document including the use of information from the medical records for research purposes. The authors propose that the pro-inflammatory cytokines produced by TLR ligand (LPS/aCpG) stimulation bind to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.